Rituximab
"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
Descriptor ID |
D000069283
|
MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Antibody, Rituximab CD20
- Rituximab CD20 Antibody
IDEC-C2B8 Antibody- IDEC-C2B8 Antibody
- IDEC C2B8 Antibody
- IDECC2B8 Antibody
- IDEC-C2B8
- IDEC C2B8
- IDECC2B8
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2013 | 0 | 1 | 1 | 2021 | 0 | 1 | 1 | 2023 | 0 | 1 | 1 | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Maniar A, Gipson DS, Brady T, Srivastava T, Selewski DT, Greenbaum LA, Dell KM, Kaskel F, Massengill S, Tran C, Trachtman H, Lafayette R, Almaani S, Hingorani S, Wang CS, Reidy K, Cara-Fuentes G, Gbadegesin R, Myers K, Sethna CB. Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study. Pediatr Nephrol. 2024 Sep; 39(9):2691-2701.
-
Chen DP, Helmuth ME, Smith AR, Canetta PA, Ayoub I, Mucha K, Kallash M, Kopp JB, Gbadegesin R, Gillespie BW, Greenbaum LA, Parekh RS, Hunley TE, Sperati CJ, Selewski DT, Kidd J, Chishti A, Reidy K, Mottl AK, Gipson DS, Srivastava T, Twombley KE. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network. Am J Kidney Dis. 2023 06; 81(6):695-706.e1.
-
Khanal S, Bradley T. A prognostic gene signature for predicting survival outcome in diffuse large B-cell lymphoma. Cancer Genet. 2021 04; 252-253:87-95.
-
Acquazzino MA, Fischer RT, Langnas A, Coulter DW. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor. Pediatr Transplant. 2013 Aug; 17(5):466-71.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|